Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Nanoscale Adv ; 5(12): 3336-3347, 2023 Jun 13.
Artigo em Inglês | MEDLINE | ID: mdl-37325521

RESUMO

Disulfiram (DSF) has been used as a hangover drug for more than seven decades and was found to have potential in cancer treatment, especially mediated by copper. However, the uncoordinated delivery of disulfiram with copper and the instability of disulfiram limit its further applications. Herein, we synthesize a DSF prodrug using a simple strategy that could be activated in a specific tumor microenvironment. Poly amino acids are used as a platform to bind the DSF prodrug through the B-N interaction and encapsulate CuO2 nanoparticles (NPs), obtaining a functional nanoplatform Cu@P-B. In the acidic tumor microenvironment, the loaded CuO2 NPs will produce Cu2+ and cause oxidative stress in cells. At the same time, the increased reactive oxygen species (ROS) will accelerate the release and activation of the DSF prodrug and further chelate the released Cu2+ to produce the noxious copper diethyldithiocarbamate complex, which causes cell apoptosis effectively. Cytotoxicity tests show that the DSF prodrug could effectively kill cancer cells with only a small amount of Cu2+ (0.18 µg mL-1), inhibiting the migration and invasion of tumor cells. In vitro and in vivo experiments have demonstrated that this functional nanoplatform could kill tumor cells effectively with limited toxic side effects, showing a new perspective in DSF prodrug design and cancer treatment.

2.
J Cell Mol Med ; 26(4): 1144-1155, 2022 02.
Artigo em Inglês | MEDLINE | ID: mdl-35001506

RESUMO

High glucose (HG) is one of the basic factors of diabetic nephropathy (DN), which leads to high morbidity and disability. During DN, the expression of glomerular glucose transporter 1 (GLUT1) increases, but the relationship between HG and GLUT1 is unclear. Glomerular mesangial cells (GMCs) have multiple roles in HG-induced DN. Here, we report prominent glomerular dysfunction, especially GMC abnormalities, in DN mice, which is closely related to GLUT1 alteration. In vivo studies have shown that BBR can alleviate pathological changes and abnormal renal function indicators of DN mice. In vitro, BBR (30, 60 and 90 µmol/L) not only increased the proportion of G1 phase cells but also reduced the proportion of S phase cells under HG conditions at different times. BBR (60 µmol/L) significantly reduced the expression of PI3K-p85, p-Akt, p-AS160, membrane-bound GLUT1 and cyclin D1, but had almost no effect on total protein. Furthermore, BBR significantly declined the glucose uptake and retarded cyclin D1-mediated GMC cell cycle arrest in the G1 phase. This study demonstrated that BBR can inhibit the development of DN, which may be due to BBR inhibiting the PI3K/Akt/AS160/GLUT1 signalling pathway to regulate HG-induced abnormal GMC proliferation and the cell cycle, supporting BBR as a potential therapeutic drug for DN.


Assuntos
Berberina , Diabetes Mellitus , Nefropatias Diabéticas , Animais , Berberina/farmacologia , Ciclo Celular , Divisão Celular , Proliferação de Células , Diabetes Mellitus/patologia , Nefropatias Diabéticas/patologia , Glucose/metabolismo , Transportador de Glucose Tipo 1/genética , Transportador de Glucose Tipo 1/metabolismo , Células Mesangiais/metabolismo , Camundongos , Fosfatidilinositol 3-Quinases/metabolismo , Proteínas Proto-Oncogênicas c-akt/metabolismo
3.
J Diabetes Investig ; 11(2): 297-306, 2020 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-31336024

RESUMO

AIMS/INTRODUCTION: Amelioration of renal impairment is the key to diabetic nephropathy (DN) therapy. The progression of DN is closely related to podocyte dysfunction, but the detailed mechanism has not yet been clarified. The present study aimed to explore the renal impairment amelioration effect of berberine and related mechanisms targeting podocyte dysfunction under the diabetic state. MATERIALS AND METHODS: Streptozotocin (35 mg/kg) was used to develop a DN rat model together with a high-glucose/high-lipid diet. Renal functional parameters and glomerular ultrastructure changes were recorded. The alterations of phosphatidylinositol 3-kinase (PI3K), protein kinase B (Akt) and phosphorylated Akt in the kidney cortex were determined by western blot. Meanwhile, podocyte dysfunction was induced and treated with berberine and LY294002. After that, podocyte adhesion functional parameters, protein biomarker and the alterations of the PI3K-Akt pathway were detected. RESULTS: Berberine reduces the increased levels of biochemical indicators, and significantly improves the abnormal expression of PI3K, Akt and phosphorylated Akt in a rat kidney model. In vitro, a costimulating factor could obviously reduce the podocyte adhesion activity, including decreased expression of nephrin, podocin and adhesion molecule α3ß1 levels, to induce podocyte dysfunction, and the trends were markedly reversed by berberine and LY294002 therapy. Furthermore, reduction of PI3K and phosphorylated Akt levels were observed in the berberine (30 and 60 µmol/L) and LY294002 (40 µmol/L) treatment group, but the Akt protein expression showed little change. CONCLUSIONS: Berberine could be a promising antidiabetic nephropathy drug through ameliorating renal impairment and inhibiting podocyte dysfunction in diabetic rats, and the underlying molecular mechanisms might be involved in the regulation of the PI3K-Akt signaling pathway.


Assuntos
Berberina/administração & dosagem , Nefropatias Diabéticas/metabolismo , Fosfatidilinositol 3-Quinase/metabolismo , Podócitos/efeitos dos fármacos , Podócitos/metabolismo , Animais , Glicemia/efeitos dos fármacos , Nefropatias Diabéticas/induzido quimicamente , Nefropatias Diabéticas/patologia , Modelos Animais de Doenças , Masculino , Proteínas Proto-Oncogênicas c-akt/metabolismo , Ratos Sprague-Dawley , Transdução de Sinais/efeitos dos fármacos , Estreptozocina/administração & dosagem , Fator de Crescimento Transformador beta1/metabolismo
4.
J Paediatr Child Health ; 56(2): 231-236, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31408250

RESUMO

AIM: To examine the association of life-style factors, including second-hand smoke, with dental caries among 3-year-old children in Wuxi, China. METHODS: A multi-stage stratified random cluster sampling method was used, and 283 children were recruited. The prevalence of dental caries was 29.3% (83/283). RESULTS: Univariate analysis indicated that the possible related factors of dental caries included sleep duration, interest in snacks, candy, exposure to second-hand smoke and weight of birth (all P < 0.05). Meanwhile, multivariate logistic regression analysis suggested that children who had used fluoride were less susceptible to dental caries than those who had not used fluoride before (P < 0.05). Moreover, the risk of dental caries in children who were very interested in snacks was greater than those with little interest in snacks (P < 0.05). CONCLUSIONS: Life-style behaviours are crucial factors and should attract enough attention. There might be a potential negative effect of second-hand smoke on the deciduous caries, but it still requires further studies. A co-ordinated effort by health-care providers, policymakers and health institutions has successfully improved children's oral health and the awareness of hygiene knowledge among citizens in Wuxi city.


Assuntos
Cárie Dentária , Poluição por Fumaça de Tabaco , Pré-Escolar , China/epidemiologia , Estudos Transversais , Índice CPO , Cárie Dentária/epidemiologia , Cárie Dentária/etiologia , Humanos , Estilo de Vida , Prevalência , Fatores de Risco , Poluição por Fumaça de Tabaco/efeitos adversos
5.
Eur J Pharmacol ; 824: 185-192, 2018 Apr 05.
Artigo em Inglês | MEDLINE | ID: mdl-29378192

RESUMO

Diabetic nephropathy is the most common microvascular complications of diabetes. Berberine is the main active ingredient of Coptis chinensis and previous studies have been showed that berberine could delay the progression of diabetic nephropathy by regulating related cytokines and signaling pathways. Glomerular mesangial cells and podocytes are two vital indigenous cells of kidney and interaction between these two cellular components via exosomes might affect function of glomerulus in diabetic nephropathy condition. On the basis of our previous studies, transwell systems were used to demonstrate that the exosomes released by glomerular mesangial cells induced by the high glucose were involved in podocytes injury. The current study demonstrates that berberine can reduce TGFß1 in exosomes released by high glucose-induced glomerular mesangial cells. Berberine-treated high glucose-induced exosomes which are secreted by glomerular mesangial cells can protect damage of podocytes by reducing apoptosis and increasing adhesion. These results suggest that berberine could protect the function of podocytes through inhibiting the transfer of TGFß1 from the glomerular mesangial cells to the podocytes, which is one of the potential mechanisms of protective effect of berberine on diabetic nephropathy.


Assuntos
Berberina/farmacologia , Exossomos/patologia , Glucose/efeitos adversos , Fosfatidilinositol 3-Quinases/metabolismo , Podócitos/efeitos dos fármacos , Proteínas Proto-Oncogênicas c-akt/metabolismo , Fator de Crescimento Transformador beta1/metabolismo , Animais , Citoproteção/efeitos dos fármacos , Relação Dose-Resposta a Droga , Células Mesangiais/citologia , Podócitos/patologia , Ratos , Transdução de Sinais/efeitos dos fármacos
6.
Mol Biol Rep ; 41(5): 3339-47, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24488262

RESUMO

Diabetic nephropathy (DN) is a major cause of morbidity and mortality in diabetic patients. Effective therapies to prevent the development of this disease and to improve advanced kidney injury are required. Berberine (BBR) has preventive effects on diabetes and its complications. This study is to investigate the effects of BBR on the expression of E-prostanoid receptors (EPs) in rats with high-fat diet and streptozotocin (STZ)-induced DN and underlying molecular mechanisms of BBR on DN rats. DN model was induced in male Sprague-Dawley rats with high-fat diet and low dose of STZ injection. BBR (50, 100, 200 mg/kg/d) were orally administered to rats after STZ injection and conducted for 8 weeks. The levels of interleukin-6 (IL-6) and prostaglandin E2 (PGE2) in renal cortex were measured by enzyme-linked immunosorbent assay. Expression of EPs receptors (EP1-EP4) were determined by western blotting. Remarkable renal damage, hyperglycemia and hyperlipidemia were observed in DN rats. BBR could restore renal functional parameters, suppress alterations in histological and ultrastructural changes in the kidney tissues, improve glucose and lipid metabolism disorders, and increase cAMP levels compared with those of DN model group (Wang et al. in Mol Biol Rep 40:2405-2418, 2013). The level of IL-6 and PGE2 were significantly increased in DN model group compared with normal group, BBR could apparently reduced the level of IL-6 and PGE2. Furthermore, the expression of EP1 and EP3 were both increased and EP4 was lessened in the DN model group compared with normal group, BBR could down-regulate total protein expression of EP1 and EP3 of renal cortex in DN rats and up-regulate the expression of EP4, and there is no significant difference on the expression of EP2 among all groups. These studies demonstrate, for the first time, that BBR exerts renoprotection in high-fat diet and STZ-induced DN rats by modulating the proteins expression of EPs in EP-G protein-cAMP signaling pathway.


Assuntos
Berberina/farmacologia , Diabetes Mellitus Experimental/metabolismo , Nefropatias Diabéticas/metabolismo , Receptores de Prostaglandina E/metabolismo , Animais , Diabetes Mellitus Experimental/genética , Nefropatias Diabéticas/genética , Dinoprostona/metabolismo , Modelos Animais de Doenças , Regulação da Expressão Gênica/efeitos dos fármacos , Interleucina-6/metabolismo , Córtex Renal/metabolismo , Córtex Renal/patologia , Masculino , Família Multigênica/genética , Ratos , Receptores de Prostaglandina E/genética
7.
J Recept Signal Transduct Res ; 33(1): 14-27, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23327583

RESUMO

Prostanoids, that is, prostaglandins (PGs) PGE(2), PGF(2α), PGI(2), PGD(2) and thromboxane A(2)(TXA(2)), are the oldest members of the eicosanoid family. The PGs are a family of lipid mediators formed in response to various stimuli. They are transported into the extracellular microenvironment by specific multidrug resistance-associated proteins (MRPs) after synthesis. Once exported to the microenvironment, prostanoids bind to G-protein coupled receptors that contain seven transmembrane spanning domains. There are eight types of the prostanoid receptors conserved in mammals from mouse to human. They are the PGD receptor (DP), four subtypes of the PGE receptor (EP(1), EP(2), EP(3) and EP(4)), the PGF receptor (FP), PGI receptor (IP) and TXA receptor (TP). Recently, several studies have revealed the roles of PG receptor signaling in various pathological conditions, and suggest that selective manipulation of the prostanoid receptors may be beneficial in treatment of the pathological conditions. Here we review these recent findings of roles of prostanoid receptor signaling and their therapeutic implications.


Assuntos
Neoplasias/metabolismo , Prostaglandinas/metabolismo , Receptores de Prostaglandina/metabolismo , Transdução de Sinais , Animais , Progressão da Doença , Humanos
8.
Mol Biol Rep ; 40(6): 3913-23, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23266672

RESUMO

Diabetic nephropathy (DN) is a progressive kidney disease that is caused by injury to glomerulus and glomerular mesangial cells (MCs) proliferation play a critical role in the pathogenesis of DN. The current studies were undertaken to investigate the protective effects and the possible molecular mechanism of berberine on streptozotocin (STZ)-induced DN rats. Male Wistar rats were randomly assigned to normal control and DN groups of comparable age. Three DN groups received 50, 100 and 200 mg/kg of berberine for 8 weeks via daily intragastrically, respectively. The G proteins-adenylyl cyclase (AC)-cAMP signaling pathway and glomerular MCs proliferation were examined in STZ-induced diabetic rat kidney. Enhanced MCs proliferation and remarkable renal injury were concomitant with activation of Gαi and inhibition of Gαs and cAMP in DN model group. Berberine treatment for 8 weeks abolished the above changes by upregulating the expression of Gαs protein and downregulating the expression of Gαi protein, increasing cAMP level, and inhibiting MCs proliferation compared with model group. Taken together, for the first time, these results demonstrated that berberine can relieve renal injury in DN rats through mediating G proteins-AC-cAMP signaling pathway and inhibiting the abnormal proliferation of MCs by increasing cAMP level, suggesting that berberine could be a potential therapeutic agent for the treatment of DN.


Assuntos
Adenilil Ciclases/metabolismo , Berberina/uso terapêutico , AMP Cíclico/metabolismo , Diabetes Mellitus Experimental/tratamento farmacológico , Nefropatias Diabéticas/tratamento farmacológico , Proteínas de Ligação ao GTP/metabolismo , Transdução de Sinais , Animais , Berberina/farmacologia , Glicemia/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Colágeno Tipo IV/metabolismo , Fator de Crescimento do Tecido Conjuntivo/metabolismo , Diabetes Mellitus Experimental/sangue , Diabetes Mellitus Experimental/complicações , Diabetes Mellitus Experimental/patologia , Nefropatias Diabéticas/sangue , Nefropatias Diabéticas/complicações , Nefropatias Diabéticas/patologia , Jejum/sangue , Fibronectinas/metabolismo , Imuno-Histoquímica , Rim/efeitos dos fármacos , Rim/patologia , Masculino , Células Mesangiais/efeitos dos fármacos , Células Mesangiais/metabolismo , Células Mesangiais/patologia , Ratos , Ratos Wistar , Transdução de Sinais/efeitos dos fármacos , Fator de Crescimento Transformador beta1/metabolismo
9.
Mol Biol Rep ; 40(3): 2405-18, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23196710

RESUMO

Berberine (BBR), an effective compound of Chinese traditional herbal medicine, has preventive effects on diabetes and its complications. In this study, we investigated the therapeutic effects and underlying molecular mechanisms of BBR in rats with high-fat diet and streptozotocin (STZ)-induced diabetic nephropathy model. BBR (50, 100, 200 mg/kg/d) were orally administered to male Sprague-Dawley rats after STZ injection and conducted for 8 weeks. Renal damage was evaluated by kidney weight to body weight ratio (KW/BW), urine microalbumin (UMAlb), urine protein for 24 h (UP24 h), urine creatinine (UCr), and histological examination. Type IV collagen and transforming growth factor-beta1 (TGF-ß1) were detected by immunohistochemistry and ultrastructure of glomeruli was observed. Fasting blood glucose (FBG),serum creatinine (SCr), blood urea nitrogen (BUN), total cholesterol (TC), triglyceride (TG), high-density lipoprotein-cholesterol (HDL-c), low-density lipoprotein-cholesterol (LDL-c) in serum and G protein-coupled receptor kinases (GRKs), cAMP in kidney were measured. Remarkable renal damage, hyperglycemia and hyperlipidemia were observed in DN rats. BBR could restore renal functional parameters, suppress alterations in histological and ultrastructural changes in the kidney tissues, improve glucose and lipid metabolism disorders, and increase cAMP levels compared with those of DN model group. Furthermore, BBR down-regulated total protein expression of GRK2, GRK3 and up-regulated expression of GRK6 of renal cortex in DN rats, but had a slight effects on GRK4 and GRK5. These studies demonstrate, for the first time, that BBR exerts renoprotection in high-fat diet and STZ-induced DN rats by modulating the proteins expression of GRKs in G protein- AC-cAMP signaling pathway.


Assuntos
Berberina/farmacologia , Diabetes Mellitus Experimental/complicações , Nefropatias Diabéticas/tratamento farmacológico , Nefropatias Diabéticas/etiologia , Substâncias Protetoras/farmacologia , Animais , Berberina/administração & dosagem , Glicemia/efeitos dos fármacos , Peso Corporal/efeitos dos fármacos , AMP Cíclico/metabolismo , Diabetes Mellitus Experimental/etiologia , Nefropatias Diabéticas/patologia , Nefropatias Diabéticas/fisiopatologia , Dieta Hiperlipídica/efeitos adversos , Modelos Animais de Doenças , Jejum/sangue , Quinases de Receptores Acoplados a Proteína G/metabolismo , Rim/efeitos dos fármacos , Rim/patologia , Rim/fisiopatologia , Testes de Função Renal , Masculino , Tamanho do Órgão , Substâncias Protetoras/administração & dosagem , Ratos , Estreptozocina/administração & dosagem , Estreptozocina/efeitos adversos
10.
Adv Ther ; 24(3): 679-90, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17660179

RESUMO

The present study was carried out to investigate the effects of catechin on adjuvant arthritis (AA) in the rat and its possible mechanisms of action. AA was induced by metatarsal footpad injection with complete Freund's adjuvant in male Sprague-Dawley rats. The secondary inflammatory reaction was evaluated through assessment of hind paw swelling, polyarthritis index, and pain response. Proliferation of synoviocytes and the activity of interleukin-1 were examined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Tumor necrosis factor-alpha, prostaglandin E(2) (PGE(2)), and cyclic adenosine monophosphate levels in synoviocytes were measured by radioimmunoassay. The PGE(2) receptor, EP(2), was analyzed by Western blot analysis. Intragastric administration of catechin (60 and 120 mg/kg) significantly suppressed secondary inflammatory paw swelling, pain response, and polyarthritis index. It also inhibited production of interleukin-1, tumor necrosis factor-alpha, and PGE(2) and increased cyclic adenosine monophosphate levels in rats with AA. In the immunoblot analysis, catechin could upregulate expression of EP(2) in the synoviocytes of rats with AA. The results showed that catechin reduced secondary inflammation in rats with AA; this outcome reflects its ability to mediate cAMP levels, upregulate expression of EP(2), and inhibit secretion of proinflammatory cytokines in rats with AA.


Assuntos
Artrite Reumatoide/tratamento farmacológico , Catequina/farmacologia , Fitoterapia , Extratos Vegetais/farmacologia , Chá , Animais , Artrite Experimental/tratamento farmacológico , AMP Cíclico/metabolismo , Citocinas/antagonistas & inibidores , Cápsula Articular/citologia , Cápsula Articular/efeitos dos fármacos , Masculino , Ratos , Ratos Sprague-Dawley , Receptores de Prostaglandina E/efeitos dos fármacos , Receptores de Prostaglandina E/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA